Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Executive Summary
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
You may also be interested in...
Leo Pharma Gets Patient-Centric On The Frontiers Of Psoriasis
Denmark’s dermatology specialist Leo Pharma has linked up with a U.S. psoriasis patient group, the National Psoriasis Foundation, to target innovation on unmet clinical needs.
Resolve Scores The Option Of An Exit With Takeda Tie-Up
Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.
Jazz And Concert In Tune On Xyrem
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.